Background: Primary diffuse leptomeningeal primitive neuroectodermal tumor (PDL PNET) is extremely rare, with only 19 cases reported in the literature to date. We present a case of a child with rapidly progressive PDL PNET and a literature review. A 10-year-old boy presented with mood lability, hallucinations, generalized pain, enuresis, and headaches. Initial investigation failed to produce a diagnosis. The symptoms progressed to seizure, back pain, and papilledema. Imaging showed acute hydrocephalus and mild diffuse leptomeningeal enhancement without an identifiable primary lesion. Methods: The hydrocephalus was managed with a ventriculostomy - later replaced by a ventriculoperitoneal shunt after ruling out infection. A dura mater biopsy obtained prior to shunt insertion was unrevealing. Repeat MRI at the 2-month follow-up showed severe interval progression of the leptomeningeal enhancement with thick lumbar spinal subdural enhancing areas. A biopsy from the inflamed arachnoid at the L3-L4 level unveiled a leptomeningeal PNET diagnosis. Results: Despite adjuvant therapy with chemoradiation, the disease progressed, and the patient died 22 months after the initial presentation. Nineteen other cases of PDL PNET have been reported in the literature and were analyzed. Conclusion: Primary leptomeningeal PNET is an extremely rare disease. Optimal treatment is not well established, and the prognosis is very poor.

Keywords:
Primary diffuse leptomeningeal primitive neuroectodermal tumor, Leptomeningeal tumor, Spine, Shunt, Biopsy
1.
Hart MN, Earle KM: Primitive neuroectodermal tumors of the brain in children. Cancer 1973;32:890-897.
2.
Gandhi R, Babu R, Cummings TJ, Adamson C: Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location. J Neurooncol 2013;114:141-148.
3.
Crouse DT, Pfaff JK, Carpentieri U: Primitive neuroectodermal tumor presenting as meningitis. Clin Pediatr (Phila) 1985;24:586, 589-590.
4.
Ferrara M, Bizzozero L, Fiumara E, D'Angelo V, Corona C, Colombo N: “Primary” leptomeningeal dissemination of medulloblastoma. Report of an unusual case. J Neurosurg Sci 1989;33:219-223.
5.
Fujii M, Orita T, Nishizaki T, Aoki H, Tanaka K: Primitive neuroectodermal tumor of the leptomeninges. Neuroradiology 1991;33:260-263.
6.
Hope JK, Armstrong DA, Babyn PS, Humphreys RR, Harwood-Nash DC, Chuang SH, Marks PV: Primary meningeal tumors in children: Correlation of clinical and CT findings with histologic type and prognosis. Am J Neuroradiol 1992;13:1353-1364.
7.
Jennings MT, Slatkin N, D'Angelo M, Ketonen L, Johnson MD, Rosenblum M, Creasy J, Tulipan N, Walker R: Neoplastic meningitis as the presentation of occult primitive neuroectodermal tumors. J Child Neurol 1993;8:306-312.
8.
Szpak GM, Papierz W, Liberski PP, Kulczycki J, Kryst-Widźgowska T, Dymecki J: Primitive neuroectodermal tumor (PNET). A case report. Folia Neuropathol 1995;33:35-40.
9.
Mendal RC, Pollay M, Bobele GB, Leech RW, Brumback RA: Primary primitive neuroectodermal tumor of the leptomeninges. J Child Neurol 1996;11:404-407.
10.
Ebinger F, Brühl K, Gutjahr P: Early diffuse leptomeningeal primitive neuroectodermal tumors can escape detection by magnetic resonance imaging. Childs Nerv Syst 2000;16:398-401.
11.
Begemann M, Lyden D, Rosenblum MK, Lis E, Wolden S, Antunes NL, Dunkel IJ: Primary leptomeningeal primitive neuroectodermal tumor. J Neurooncol 2003;63:299-303.
12.
Kim AV, Shim KV, Kim DS, Khachaturian VA, Choi DY: The leptomeningeal form of primary neuroectodermal tumor (in Russian). Zh Vopr Neirokhir Im N N Burdenko 2007:45-48.
13.
Junewick J: Leptomeningeal carcinomatosis. History 2009;5:26.
14.
Foreid H, Barroso C, Carvalho H, Morgado C, Roque L, Pimentel J: A 22-year-old man with intracranial hypertension and impaired sensation over the perineum and left foot. Brain Pathol 2009;19:735-738.
15.
Bailey P, Robitaille Y: Primary diffuse leptomeningeal gliomatosis. Can J Neurol Sci 1985;12:278-281.
16.
Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT: Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 1996;29:75-84.
17.
Nambirajan A, Suri V, Sharma MC, Kumar R, Garg A, Gulati S, Tandon V: A 7-year-old girl with recurrent episodes of abdominal pain, seizures, and loss of vision: primary diffuse leptomeningeal primitive neuroectodermal tumor masquerading as chronic meningitis. Neurol India 2015;63:736-742.
18.
Maher OM, Sandberg D, Kannan G, McGovern S, Ketonen L, Khatua S: Primary leptomeningeal primitive neuroectodermal tumor, MS-17. Neuro-Oncol 2014;16(suppl 5):V130.
19.
Kleihues P, Burger PC, Scheithauer BW: The new who classification of brain tumours. Brain Pathol 1993;3:255-268.
20.
Kosnik EJ, Boesel CP, Bay J, Sayers MP: Primitive neuroectodermal tumors of the central nervous system in children. J Neurosurg 1978;48:741-746.
21.
Kepes JJ, Belton K, Roessmann U, Ketcherside WJ: Primitive neuroectodermal tumors of the cauda equina in adults with no detectable primary intracranial neoplasm - three case studies. Clin Neuropathol 1985;4:1-11.
22.
Liu HM, Yang WC, Garcia RL, Noh JM, Malhotra V, Leeds NE: Intraspinal primitive neuroectodermal tumor arising from the sacral spinal nerve root. J Comput Tomogr 1987;11:350-354.
23.
McDermott VG, el-Jabbour JN, Sellar RJ, Bell J: Primitive neuroectodermal tumour of the cauda equina. Neuroradiology 1994;36:228-230.
24.
Yavuz AA, Yaris N, Yavuz MN, Sari A, Reis AK, Aydin F: Primary intraspinal primitive neuroectodermal tumor: case report of a tumor arising from the sacral spinal nerve root and review of the literature. Am J Clin Oncol 2002;25:135-139.
25.
Packer RJ, Siegel KR, Sutton LN, Litmann P, Bruce DA, Schut L: Leptomeningeal dissemination of primary central nervous system tumors of childhood. Ann Neurol 1985;18:217-221.
26.
Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, Jenkins JJ, Langston JW, Liu A, Kun LE, Heideman RL: Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 1999;17:3234-3237.
27.
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, et al: New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016;164:1060-1072.
28.
Choi SH, Kim SH, Shim KW, Han JW, Choi J, Kim DS, Lyu CJ, Kim JW, Suh CO, Cho J: Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors. PLoS One 2016;11: e0153443.
29.
Wang KC, Chi JG, Cho BK, Choi KS: Biological behavior of the primitive neuroectodermal tumor. Seoul J Med 1988;29:293-303.
30.
Rubinstein LJ: Justification for cytogenetic scheme of embryonal central neuroepithelial tumors; in Fields WS (ed): Primary Brain Tumors: A Review of Histologic Classification. New York, Springer, 1989, pp 16-46.
31.
Zeltzer PM, Boyett J, Finlay J: Prognostic factors for survival differ in high-risk infra-and supratentorial primitive neuroectodermal tumors. Pediatric Neurosurg 1993;19:333.
32.
Allen JC, Epstein F: Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis. J Neurosurg 1982;57:446-451.
33.
Ray GL, Buchsbaum JC, McMullen KP, Simoneaux RV, Hines M, Douglas JG, Johnstone PA: Definitive treatment of leptomeningeal spinal metastases in children. Pediatr Blood Cancer 2013;60:1839-1841.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.